R
RENB
vs
S&P 500
S&P 500
Over the past 12 months, RENB has underperformed S&P 500, delivering a return of -89% compared to the S&P 500's +14% growth.
Stocks Performance
RENB vs S&P 500
Performance Gap
RENB vs S&P 500
Performance By Year
RENB vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Renovaro Biosciences Inc
Glance View
Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 11 full-time employees. The company went IPO on 2014-11-18. The company is focused on developing allogeneic cell and gene therapies to promote stronger immune system responses for long-term or life-long cancer remission in cancers and to treat or cure infectious diseases, such as Human Immunodeficiency Virus (HIV) and Hepatitis B virus (HBV) infection. The Allogeneic Cell Therapy platform has a human immune system, which is designed to recognize the self and destroy otherness or non-self, such as bacteria, viruses and cancer cells. Its product candidates include ENOB-HV-01, which utilizes a cellular- and immunotherapy approach that could provide both preventative and therapeutic vaccines for HIV and ENOB-DC-11, which is a genetically modified allogeneic dendritic cell therapeutic vaccine as product for long-term remission of solid tumors. The company is also exploring ENOB-HV-21, a treatment for HIV with allogeneic natural killer and gamma delta t-cells.
